Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

HBV Immune-Therapy: From Molecular Mechanisms to Clinical Applications.

Boni C, Barili V, Acerbi G, Rossi M, Vecchi A, Laccabue D, Penna A, Missale G, Ferrari C, Fisicaro P.

Int J Mol Sci. 2019 Jun 5;20(11). pii: E2754. doi: 10.3390/ijms20112754. Review.

2.

Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis.

Boni C, Janssen HLA, Rossi M, Yoon SK, Vecchi A, Barili V, Yoshida EM, Trinh H, Rodell TC, Laccabue D, Alfieri A, Brillo F, Fisicaro P, Acerbi G, Pedrazzi G, Andreone P, Cursaro C, Margotti M, Santoro R, Piazzolla V, Brunetto MR, Coco B, Cavallone D, Zhao Y, Joshi A, Woo J, Lau AH, Gaggar A, Subramanian GM, Massetto B, Fung S, Ahn SH, Ma X, Mangia A, Ferrari C.

Gastroenterology. 2019 Jul;157(1):227-241.e7. doi: 10.1053/j.gastro.2019.03.044. Epub 2019 Mar 28.

PMID:
30930022
3.

Strategies to overcome HBV-specific T cell exhaustion: checkpoint inhibitors and metabolic re-programming.

Fisicaro P, Boni C, Barili V, Laccabue D, Ferrari C.

Curr Opin Virol. 2018 Jun;30:1-8. doi: 10.1016/j.coviro.2018.01.003. Epub 2018 Feb 4. Review.

PMID:
29414066
4.

TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues.

Boni C, Vecchi A, Rossi M, Laccabue D, Giuberti T, Alfieri A, Lampertico P, Grossi G, Facchetti F, Brunetto MR, Coco B, Cavallone D, Mangia A, Santoro R, Piazzolla V, Lau A, Gaggar A, Subramanian GM, Ferrari C.

Gastroenterology. 2018 May;154(6):1764-1777.e7. doi: 10.1053/j.gastro.2018.01.030. Epub 2018 Jan 31.

PMID:
29378197
5.

T cell regulation in HBV-related chronic liver disease.

Ferrari C, Boni C, Rossi M, Vecchi A, Barili V, Laccabue D, Fisicaro P, Missale G.

J Hepatol. 2017 May;66(5):1096-1098. doi: 10.1016/j.jhep.2016.10.002. Epub 2017 Feb 8. No abstract available.

PMID:
28189261
6.

Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy.

Negri FV, Musolino A, Naldi N, Bortesi B, Missale G, Laccabue D, Zerbini A, Camisa R, Chernyschova N, Bisagni G, Loupakis F, Ruzzo A, Neri TM, Ardizzoni A.

Pharmacogenomics J. 2014 Feb;14(1):14-9. doi: 10.1038/tpj.2012.54. Epub 2013 Jan 8.

PMID:
23296156
7.

Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.

Boni C, Laccabue D, Lampertico P, Giuberti T, Viganò M, Schivazappa S, Alfieri A, Pesci M, Gaeta GB, Brancaccio G, Colombo M, Missale G, Ferrari C.

Gastroenterology. 2012 Oct;143(4):963-73.e9. doi: 10.1053/j.gastro.2012.07.014. Epub 2012 Jul 14.

PMID:
22796241
8.

Increased levels of arginase in patients with acute hepatitis B suppress antiviral T cells.

Sandalova E, Laccabue D, Boni C, Watanabe T, Tan A, Zong HZ, Ferrari C, Bertoletti A.

Gastroenterology. 2012 Jul;143(1):78-87.e3. doi: 10.1053/j.gastro.2012.03.041. Epub 2012 Apr 1.

PMID:
22475535
9.

Peginterferon-α does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis.

Penna A, Laccabue D, Libri I, Giuberti T, Schivazappa S, Alfieri A, Mori C, Canetti D, Lampertico P, Viganò M, Colombo M, Loggi E, Missale G, Ferrari C.

J Hepatol. 2012 Jun;56(6):1239-46. doi: 10.1016/j.jhep.2011.12.032. Epub 2012 Feb 9.

PMID:
22326467
10.

Contribution of herpesvirus specific CD8 T cells to anti-viral T cell response in humans.

Sandalova E, Laccabue D, Boni C, Tan AT, Fink K, Ooi EE, Chua R, Shafaeddin Schreve B, Ferrari C, Bertoletti A.

PLoS Pathog. 2010 Aug 19;6(8):e1001051. doi: 10.1371/journal.ppat.1001051.

11.

Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response.

Zerbini A, Pilli M, Laccabue D, Pelosi G, Molinari A, Negri E, Cerioni S, Fagnoni F, Soliani P, Ferrari C, Missale G.

Gastroenterology. 2010 May;138(5):1931-42. doi: 10.1053/j.gastro.2009.12.051. Epub 2010 Jan 11.

PMID:
20060829
12.

Concomitant downregulation of proliferation/survival pathways dependent on FGF-R3, JAK2 and BCMA in human multiple myeloma cells by multi-kinase targeting.

Cassinelli G, Ronchetti D, Laccabue D, Mattioli M, Cuccuru G, Favini E, Nicolini V, Greco A, Neri A, Zunino F, Lanzi C.

Biochem Pharmacol. 2009 Nov 1;78(9):1139-47. doi: 10.1016/j.bcp.2009.06.023. Epub 2009 Jun 23.

PMID:
19555670
13.

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, Neri TM, Ardizzoni A.

J Clin Oncol. 2008 Apr 10;26(11):1789-96. doi: 10.1200/JCO.2007.14.8957. Epub 2008 Mar 17.

PMID:
18347005
14.

Increased immunostimulatory activity conferred to antigen-presenting cells by exposure to antigen extract from hepatocellular carcinoma after radiofrequency thermal ablation.

Zerbini A, Pilli M, Fagnoni F, Pelosi G, Pizzi MG, Schivazappa S, Laccabue D, Cavallo C, Schianchi C, Ferrari C, Missale G.

J Immunother. 2008 Apr;31(3):271-82. doi: 10.1097/CJI.0b013e318160ff1c.

PMID:
18317360
15.

Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection.

Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, Laccabue D, Zerbini A, Cavalli A, Missale G, Bertoletti A, Ferrari C.

J Virol. 2007 Apr;81(8):4215-25. Epub 2007 Feb 7.

16.

Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1.

Cassinelli G, Lanzi C, Petrangolini G, Tortoreto M, Pratesi G, Cuccuru G, Laccabue D, Supino R, Belluco S, Favini E, Poletti A, Zunino F.

Mol Cancer Ther. 2006 Sep;5(9):2388-97.

17.

Biocompatibility and tissue interactions of a new filler material for medical use.

Zarini E, Supino R, Pratesi G, Laccabue D, Tortoreto M, Scanziani E, Ghisleni G, Paltrinieri S, Tunesi G, Nava M.

Plast Reconstr Surg. 2004 Sep 15;114(4):934-42.

PMID:
15468401
18.

Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.

Cuccuru G, Lanzi C, Cassinelli G, Pratesi G, Tortoreto M, Petrangolini G, Seregni E, Martinetti A, Laccabue D, Zanchi C, Zunino F.

J Natl Cancer Inst. 2004 Jul 7;96(13):1006-14.

PMID:
15240784
19.

RET/PTC oncoproteins: molecular targets of new drugs.

Lanzi C, Cassinelli G, Cuccuru G, Zanchi C, Laccabue D, Zunino F.

Tumori. 2003 Sep-Oct;89(5):520-2.

PMID:
14870776
20.

Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine.

Pisano C, Pratesi G, Laccabue D, Zunino F, Lo Giudice P, Bellucci A, Pacifici L, Camerini B, Vesci L, Castorina M, Cicuzza S, Tredici G, Marmiroli P, Nicolini G, Galbiati S, Calvani M, Carminati P, Cavaletti G.

Clin Cancer Res. 2003 Nov 15;9(15):5756-67.

21.

Antiangiogenic effects of the novel camptothecin ST1481 (gimatecan) in human tumor xenografts.

Petrangolini G, Pratesi G, De Cesare M, Supino R, Pisano C, Marcellini M, Giordano V, Laccabue D, Lanzi C, Zunino F.

Mol Cancer Res. 2003 Oct;1(12):863-70.

22.

IDN 5390: an oral taxane candidate for protracted treatment schedules.

Pratesi G, Laccabue D, Lanzi C, Cassinelli G, Supino R, Zucchetti M, Frapolli R, D'Incalci M, Bombardelli E, Morazzoni P, Riva A, Zunino F.

Br J Cancer. 2003 Mar 24;88(6):965-72.

23.

Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer.

Cassinelli G, Lanzi C, Supino R, Pratesi G, Zuco V, Laccabue D, Cuccuru G, Bombardelli E, Zunino F.

Clin Cancer Res. 2002 Aug;8(8):2647-54.

24.

A novel taxane active against an orthotopically growing human glioma xenograft.

Laccabue D, Tortoreto M, Veneroni S, Perego P, Scanziani E, Zucchetti M, Zaffaroni M, D'Incalci M, Bombardelli E, Zunino F, Pratesi G.

Cancer. 2001 Dec 15;92(12):3085-92.

PMID:
11753988

Supplemental Content

Loading ...
Support Center